Search research articles
Contact Us
Filters
Showing results (131-140 of 1,422) with videos related to
Page
of 143
Sort By:
The American Journal of Cardiology
|
March 14, 2003
Left ventricular hypertrophy and the risk of subsequent left ventricular remodeling following myocardial infarction
Hasan Jilaihawi, Sally Greaves, Jean L Rouleau, et al.
Journal of the American College of Cardiology
|
February 7, 2006
Chronic recurrent myocardial ischemic injury is significantly attenuated by pre-emptive adeno-associated virus heme oxygenase-1 gene delivery
Alok S Pachori, Luis G Melo, Lunan Zhang, et al.
Contemporary Clinical Trials
|
January 27, 2020
Adherence-adjustment in placebo-controlled randomized trials: An application to the candesartan in heart failure randomized trial
Eleanor J Murray, Brian L Claggett, Bradi Granger, et al.
The American Journal of Cardiology
|
July 16, 2005
Prognostic significance of troponin elevation and right ventricular enlargement in acute pulmonary embolism
Tudor Scridon, Cristiana Scridon, Hicham Skali, et al.
Journal of Cardiac Failure
|
August 10, 2014
Plasma galectin-3 and heart failure outcomes in MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy)
Craig M Stolen, Aram Adourian, Timothy E Meyer, et al.
European Journal of Heart Failure
|
December 15, 2024
Tailoring medical therapy for heart failure with preserved ejection fraction
Riccardo M Inciardi, Mauro Riccardi, Gianluigi Savarese, et al.
Journal of Cardiac Failure
|
January 30, 2003
Noninvasive assessment of left ventricular remodeling: concepts, techniques, and implications for clinical trials
Inder S Anand, Viorel G Florea, Scott D Solomon, et al.
European Journal of Heart Failure
|
December 29, 2018
Long-term outcomes of cardiac resynchronization therapy by left ventricular ejection fraction
Valentina Kutyifa, Katherine Vermilye, Scott D Solomon, et al.
JACC. Heart Failure
|
August 1, 2020
Reply: The PARAGON-HF Trial: Toward Extension to Patients With HF Middle Range Ejection Fraction
Jonathan W Cunningham, Muthiah Vaduganathan, Brian L Claggett, et al.
Journal of the American College of Cardiology
|
October 8, 2025
Reply: Heart Failure With Improved EF: A Transitional State Demanding Targeted Strategies?
Mauro Riccardi, Maria A Pabon, Orly Vardeny, et al.
Page
of 143
Search research articles
Search
Showing results (131-140 of 1,422) with videos related to
Sort By:
Page
of 143
The American Journal of Cardiology
|
March 14, 2003
Left ventricular hypertrophy and the risk of subsequent left ventricular remodeling following myocardial infarction
Hasan Jilaihawi, Sally Greaves, Jean L Rouleau, et al.
Journal of the American College of Cardiology
|
February 7, 2006
Chronic recurrent myocardial ischemic injury is significantly attenuated by pre-emptive adeno-associated virus heme oxygenase-1 gene delivery
Alok S Pachori, Luis G Melo, Lunan Zhang, et al.
Contemporary Clinical Trials
|
January 27, 2020
Adherence-adjustment in placebo-controlled randomized trials: An application to the candesartan in heart failure randomized trial
Eleanor J Murray, Brian L Claggett, Bradi Granger, et al.
The American Journal of Cardiology
|
July 16, 2005
Prognostic significance of troponin elevation and right ventricular enlargement in acute pulmonary embolism
Tudor Scridon, Cristiana Scridon, Hicham Skali, et al.
Journal of Cardiac Failure
|
August 10, 2014
Plasma galectin-3 and heart failure outcomes in MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy)
Craig M Stolen, Aram Adourian, Timothy E Meyer, et al.
European Journal of Heart Failure
|
December 15, 2024
Tailoring medical therapy for heart failure with preserved ejection fraction
Riccardo M Inciardi, Mauro Riccardi, Gianluigi Savarese, et al.
Journal of Cardiac Failure
|
January 30, 2003
Noninvasive assessment of left ventricular remodeling: concepts, techniques, and implications for clinical trials
Inder S Anand, Viorel G Florea, Scott D Solomon, et al.
European Journal of Heart Failure
|
December 29, 2018
Long-term outcomes of cardiac resynchronization therapy by left ventricular ejection fraction
Valentina Kutyifa, Katherine Vermilye, Scott D Solomon, et al.
JACC. Heart Failure
|
August 1, 2020
Reply: The PARAGON-HF Trial: Toward Extension to Patients With HF Middle Range Ejection Fraction
Jonathan W Cunningham, Muthiah Vaduganathan, Brian L Claggett, et al.
Journal of the American College of Cardiology
|
October 8, 2025
Reply: Heart Failure With Improved EF: A Transitional State Demanding Targeted Strategies?
Mauro Riccardi, Maria A Pabon, Orly Vardeny, et al.
Page
of 143